engleski

A phase II trial of cardioprotection with cardioxane (ICRF-187) in patients with advanced breast cancer receiving 5-fluorouracil, doxorubicin and cyclophosphamide

From January 1991 to August 1993, 237 women with metastatic breast cancer were recruited into a multicentric phase II clinical trial designed to assess the cardioprotective activity of Cardioxane. All patients were treated with 5- fluorouracil, doxorubicin, cyclophosphamide and Cardioxane, in cycles repeated every 3-4 weeks.Cardiac functions were assessed at baseline by physical examination, ECG, and rsting ultrasound left ventricle ejection fraction (LVEF).The same tests were repeated regularly after the 3rd, 6th, 8th cycle and every additional 100 mg/m2 of doxorubicin. At the end ot the study there were 212 evaluable patients.Cardioxane provided cardiac protection offering the possibility of longer doxorubicin chemotherapy.

cardioxane ; breast cancer ; doxorubicin

nije evidentirano